
Keywords: خونریزی کلونال; AML; acute myeloid leukemia; CH; clonal hematopoiesis; CHIP; clonal hematopoiesis of indeterminate potential; FDA; Food and Drug Administration; MDS; myelodysplastic syndrome; MGUS; monoclonal gammopathy of undetermined significance; MRD; minimal residual